Citizens Jmp Issues Positive Forecast for ACADIA Pharmaceuticals (NASDAQ:ACAD) Stock Price

ACADIA Pharmaceuticals (NASDAQ:ACAD) had its price target hoisted by Citizens Jmp from $34.00 to $35.00 in a research report released on Thursday,Benzinga reports. Citizens Jmp currently has a market outperform rating on the biopharmaceutical company’s stock.

Several other research firms have also weighed in on ACAD. Needham & Company LLC reaffirmed a “buy” rating and issued a $34.00 target price on shares of ACADIA Pharmaceuticals in a report on Monday, January 5th. Stifel Nicolaus reduced their price target on shares of ACADIA Pharmaceuticals from $25.00 to $24.00 and set a “hold” rating on the stock in a research report on Thursday. UBS Group raised their price objective on shares of ACADIA Pharmaceuticals from $35.00 to $40.00 and gave the stock a “buy” rating in a report on Tuesday, January 6th. Royal Bank Of Canada reduced their target price on ACADIA Pharmaceuticals from $35.00 to $31.00 and set an “outperform” rating on the stock in a report on Tuesday, February 3rd. Finally, HC Wainwright restated a “buy” rating and set a $37.00 price target on shares of ACADIA Pharmaceuticals in a research report on Tuesday, February 3rd. One equities research analyst has rated the stock with a Strong Buy rating, thirteen have given a Buy rating, five have given a Hold rating and one has assigned a Sell rating to the stock. According to data from MarketBeat, ACADIA Pharmaceuticals has a consensus rating of “Moderate Buy” and a consensus price target of $30.74.

ACADIA Pharmaceuticals Stock Down 1.3%

Shares of ACAD opened at $24.64 on Thursday. The company has a 50-day moving average price of $25.58 and a two-hundred day moving average price of $24.45. The stock has a market cap of $4.17 billion, a price-to-earnings ratio of 10.76, a P/E/G ratio of 8.73 and a beta of 0.66. ACADIA Pharmaceuticals has a 12 month low of $13.40 and a 12 month high of $28.35.

ACADIA Pharmaceuticals (NASDAQ:ACAD) last issued its earnings results on Wednesday, February 25th. The biopharmaceutical company reported $1.60 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.12 by $1.48. The business had revenue of $298.00 million during the quarter, compared to analysts’ expectations of $292.54 million. ACADIA Pharmaceuticals had a return on equity of 13.96% and a net margin of 36.49%.ACADIA Pharmaceuticals’s quarterly revenue was up 9.4% compared to the same quarter last year. During the same period in the prior year, the firm posted $0.86 EPS. Equities research analysts expect that ACADIA Pharmaceuticals will post 0.7 EPS for the current fiscal year.

Insider Transactions at ACADIA Pharmaceuticals

In other ACADIA Pharmaceuticals news, EVP Jennifer J. Rhodes sold 6,950 shares of the stock in a transaction on Monday, February 9th. The stock was sold at an average price of $23.38, for a total value of $162,491.00. Following the transaction, the executive vice president directly owned 7,609 shares in the company, valued at approximately $177,898.42. This trade represents a 47.74% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Corporate insiders own 26.50% of the company’s stock.

Institutional Trading of ACADIA Pharmaceuticals

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in the company. State Street Corp lifted its position in ACADIA Pharmaceuticals by 9.0% during the 4th quarter. State Street Corp now owns 7,910,733 shares of the biopharmaceutical company’s stock valued at $211,296,000 after purchasing an additional 655,257 shares during the period. Geode Capital Management LLC raised its stake in shares of ACADIA Pharmaceuticals by 3.4% during the fourth quarter. Geode Capital Management LLC now owns 3,239,451 shares of the biopharmaceutical company’s stock worth $86,539,000 after buying an additional 106,807 shares during the last quarter. Dimensional Fund Advisors LP lifted its holdings in ACADIA Pharmaceuticals by 4.4% in the fourth quarter. Dimensional Fund Advisors LP now owns 2,920,974 shares of the biopharmaceutical company’s stock valued at $78,019,000 after buying an additional 122,840 shares during the period. First Trust Advisors LP boosted its stake in ACADIA Pharmaceuticals by 2.8% in the second quarter. First Trust Advisors LP now owns 2,434,376 shares of the biopharmaceutical company’s stock valued at $52,509,000 after acquiring an additional 65,914 shares during the last quarter. Finally, Braidwell LP acquired a new stake in ACADIA Pharmaceuticals during the 3rd quarter worth $50,760,000. 96.71% of the stock is currently owned by institutional investors and hedge funds.

Key ACADIA Pharmaceuticals News

Here are the key news stories impacting ACADIA Pharmaceuticals this week:

• Positive Sentiment: Q4 results materially beat EPS expectations: ACAD reported $1.60 EPS (vs. $0.12 consensus) and $298M revenue, with revenue up ~9% YoY — a clear near-term fundamental positive that supports valuation re-rating. Earnings / Transcript
• Positive Sentiment: Management set 2026 revenue targets of roughly $1.2–$1.28B and highlighted commercial momentum for DAYBUE and NUPLAZID, giving investors a revenue-growth roadmap for next year. Seeking Alpha: 2026 targets
• Positive Sentiment: Multiple analyst actions lifted sentiment — TD Cowen raised its target to $37 (buy), Citizens JMP to $35 (market outperform), and Wolfe Research initiated coverage with an outperform and $33 target — signaling several firms see substantial upside from current levels. Analyst Notes
• Neutral Sentiment: Full earnings materials and call transcript/slide deck are available for detailed review (management commentary covers commercial performance and pipeline updates); useful for investors who want to dig into assumptions behind guidance. Earnings Call Transcript
• Neutral Sentiment: Short-interest reports appearing in data feeds show anomalous zero/NaN values for February; this looks like a reporting glitch and is not a reliable signal of rising short pressure.
• Negative Sentiment: Analysts and headlines flagged an EU setback for trofinetide and a mixed sales read — Zacks notes a sales miss and regulatory/cloud on trofinetide’s EU outlook, which could temper upside for pipeline-derived revenue. Zacks: EU setback
• Negative Sentiment: Some analyst trims introduced headwinds — RBC trimmed its target to $30 and Stifel cut to $24 (hold), creating mixed street sentiment even as other firms raised targets. Analyst Moves
• Negative Sentiment: Broader policy risk for midsize biotechs (debate over MFN / pricing proposals) remains an overhang for the sector and can pressure valuations if regulatory action gains traction. FierceBiotech: Policy risk

About ACADIA Pharmaceuticals

ACADIA Pharmaceuticals Inc is a biopharmaceutical company focused on the development and commercialization of innovative therapies for central nervous system (CNS) disorders. Established in 1993 and headquartered in San Diego, California, ACADIA’s research centers concentrate on conditions with significant unmet medical needs, including Parkinson’s disease psychosis, Alzheimer’s disease psychosis, and schizophrenia. The company utilizes a range of scientific platforms, including selective receptor modulation and precision-targeted compounds, to advance its portfolio of small-molecule therapeutics.

The company’s flagship product, NUPLAZID® (pimavanserin), received U.S.